Form 4: Immunocore SVP Finance & CAO Boosts Equity Holdings

Immunocore's SVP of Finance and CAO, John Goll, reported new equity awards and a tax-related share sale.

Summary

• John Goll, SVP, Finance & CAO of Immunocore Holdings plc, reported changes in his beneficial ownership of company securities.
• On February 17, 2026, Goll acquired 1,351 Ordinary Shares upon the vesting of Restricted Share Units (RSUs).
• On February 18, 2026, Goll sold 698 Ordinary Shares at a weighted average price of $32.35 per share to cover income tax liabilities from RSU vesting.
• Goll was granted an additional 7,411 Restricted Share Units (RSUs) on February 17, 2026, which will vest in four equal annual installments starting February 17, 2027.
• He also received a grant of 21,252 Employee Share Options on February 17, 2026, with an exercise price of $32.38 and an expiration date of February 16, 2036.
• The options will vest 25% on February 17, 2027, with subsequent quarterly installments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event for the insider, reflecting continued commitment and incentive alignment through new equity awards, while the tax-related sale is a routine occurrence.

Positives

• John Goll, a key executive, received significant new equity awards (7,411 RSUs and 21,252 Employee Share Options), aligning his interests with long-term shareholder value.
• The acquisition of 1,351 Ordinary Shares from RSU vesting indicates a portion of his compensation is tied to company performance and continued service.

Negatives

• The sale of 698 Ordinary Shares, while for tax purposes, represents a reduction in direct share ownership, though it's a common practice for vested equity awards.

Risks

• The vesting of new RSUs and options is contingent on John Goll's continuous service, posing a risk if his employment ceases before vesting dates.
• Future share dilution could occur as these new RSUs and options vest and are exercised, increasing the total number of outstanding shares.

Future Outlook

The future outlook for John Goll's equity holdings includes the vesting of 7,411 Restricted Share Units in four equal annual installments starting February 17, 2027, and the vesting of 21,252 Employee Share Options, with 25% vesting on February 17, 2027, followed by quarterly installments, all contingent on his continuous service.

Management Comments

• The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs").

Industry Context

StockSavvy.ai notes that this Form 4 filing details routine insider compensation activities, including the grant of new equity awards and a 'sell-to-cover' transaction for tax purposes. Such events are common across the biotechnology and pharmaceutical industries, where executive compensation often includes significant equity components to align management incentives with long-term company performance.

Comparison to Industry Standards

• The grant of Restricted Share Units (RSUs) and Employee Share Options is a standard practice in executive compensation packages within the U.S. public company landscape, particularly in high-growth sectors like biotechnology, similar to practices seen at companies like Moderna or BioNTech.
• The 'sell-to-cover' mechanism for tax obligations upon RSU vesting is a widely accepted and common method for insiders to manage tax liabilities without necessarily signaling a negative outlook on the company's stock, mirroring practices at many S&P 500 companies.

Related Party Transactions

• The acquisition of Ordinary Shares and the grant of Restricted Share Units and Employee Share Options to John Goll, a senior executive, constitute related party transactions as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of new equity awards (7,411 RSUs and 21,252 options) over time. The tax-related sale of shares is a routine event and generally has minimal impact.
• Employees (specifically John Goll): Increased long-term incentive and alignment with company performance through new equity grants.

Next Steps

• Continued service by John Goll to ensure vesting of future RSU and option grants.
• Future vesting events for the 7,411 RSUs starting February 17, 2027.
• Future vesting events for the 21,252 Employee Share Options starting February 17, 2027, and subsequent quarterly installments.

Key Dates

Recommendation

This Form 4 filing details routine insider compensation and tax-related share sales, which are common and do not typically indicate a significant change in the company's fundamental outlook or warrant a change in investment recommendation. The new equity grants align executive interests with long-term performance, which is generally positive, but the overall impact on the stock's valuation is neutral for a seasoned investor.

Keywords

Immunocore Holdings plc, IMCR, Form 4, Insider Trading, Restricted Share Units, Employee Stock Options, Equity Compensation, John Goll, SVP Finance, CAO, Share Sale, Vesting